论文部分内容阅读
目的探讨多西他赛联合替吉奥治疗晚期胃癌的疗效及安全性,为晚期胃癌的临床治疗提供参考。方法 76例晚期胃癌患者随机分为观察组和对照组,每组38例。对照组给予DPF(多西紫杉醇+顺铂+5-氟脲嘧啶)进行治疗,观察组给予多西他赛联合替吉奥进行治疗,对两组患者的近远期效果及安全性进行分析。结果观察组患者治疗总有效率显著高于对照组,中位生存期显著较长,不良反应明显较少,差异均具有统计学意义(P<0.05)。结论多西他赛联合替吉奥治疗晚期胃癌疗效较好,不良反应少,安全性较高,有效延长了患者生存期,值得临床推广。
Objective To investigate the efficacy and safety of docetaxel combined with tegaserod in the treatment of advanced gastric cancer and provide reference for the clinical treatment of advanced gastric cancer. Methods 76 patients with advanced gastric cancer were randomly divided into observation group and control group, 38 cases in each group. The control group was treated with DPF (docetaxel + cisplatin + 5-fluorouracil), and the observation group was treated with docetaxel combined with tioguanide. The short-term and long-term effects and safety of the two groups were analyzed. Results The total effective rate of observation group was significantly higher than that of control group, the median survival time was significantly longer, adverse reactions were significantly less, the difference was statistically significant (P <0.05). Conclusion docetaxel combined with tigiao for the treatment of advanced gastric cancer better efficacy, fewer adverse reactions, higher safety, effectively prolonging the survival of patients, it is worth clinical promotion.